首页> 美国卫生研究院文献>The Journal of Pediatric Pharmacology and Therapeutics : JPPT >Comparison of Polyethylene Glycol-Electrolyte Solution vs Polyethylene Glycol-3350 for the Treatment of Fecal Impaction in Pediatric Patients
【2h】

Comparison of Polyethylene Glycol-Electrolyte Solution vs Polyethylene Glycol-3350 for the Treatment of Fecal Impaction in Pediatric Patients

机译:聚乙二醇电解质溶液与聚乙二醇-3350治疗小儿粪便撞击的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

>OBJECTIVES: The objective of this study was to evaluate the safety and efficacy of polyethylene glycol-electrolyte solution vs polyethylene glycol-3350 for the treatment of fecal impaction in pediatric patients.>METHODS: A retrospective, observational, institutional review board–approved study was conducted over a 1-year time period. Patients were included in the study if they were admitted to the hospital with a diagnosis of fecal impaction or constipation and were treated with either polyethylene glycol-electrolyte solution (PEG-ES) or polyethylene glycol-3350 (PEG-3350). Patients were excluded if they were discharged prior to resolution of treatment and/or did not receive PEG-ES or PEG-3350.>RESULTS: Fifty-one patients (ranging in age from 1 month to 15 years) were evaluated: 23 patients received PEG-ES and 28 patients received PEG-3350. Sex, race, age, and weight were not statistically different between the 2 groups. Resolution of fecal impaction was not significantly different between PEG-ES vs PEG-3350 (87% and 86%, respectively; p = 0.87). There was only 1 reported side effect with PEG-3350, vs 11 reported side effects with PEG-ES (p < 0.01).>CONCLUSIONS: Theses results suggest that PEG-3350 is as effective as PEG-ES for the treatment of fecal impaction in pediatric patients and is associated with fewer side effects>.
机译:>目的:本研究的目的是评估聚乙二醇电解质溶液与聚乙二醇3350相比对小儿粪便撞击的安全性和有效性。>方法:回顾性,观察性,机构审查委员会批准的研究历时1年。如果患者入院诊断为粪便受压或便秘,并接受了聚乙二醇电解质溶液(PEG-ES)或聚乙二醇3350(PEG-3350)的治疗,则将其纳入研究。如果患者在解决方案之前出院和/或未接受PEG-ES或PEG-3350,则被排除在外。>结果:51位患者(年龄从1个月至15岁不等)进行了评估:23例患者接受了PEG-ES,28例患者接受了PEG-3350。两组之间的性别,种族,年龄和体重无统计学差异。 PEG-ES与PEG-3350之间的粪便撞击分辨率没有显着差异(分别为87%和86%; p = 0.87)。 PEG-3350的副作用只有1种,而PEG-ES的副作用只有11种(p <0.01)。>结论:这些结果表明PEG-3350与PEG-ES一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号